Jarislowsky, Fraser Ltd’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,470
| Closed | -$222K | – | 191 |
|
|
2023
Q2 | $222K | Sell |
3,470
-1,655
| -32% | -$111K | ﹤0.01% | 191 |
|
|
2023
Q1 | $355K | Sell |
5,125
-680
| -12% | -$48K | ﹤0.01% | 177 |
|
|
2022
Q4 | $418K | Sell |
5,805
-120
| -2% | -$9.05K | ﹤0.01% | 178 |
|
|
2022
Q3 | $421K | Sell |
5,925
-146
| -2% | -$10.6K | ﹤0.01% | 173 |
|
|
2022
Q2 | $467K | Hold |
6,071
| – | – | ﹤0.01% | 176 |
|
|
2022
Q1 | $443K | Hold |
6,071
| – | – | ﹤0.01% | 183 |
|
|
2021
Q4 | $378K | Sell |
6,071
-775
| -11% | -$45.5K | ﹤0.01% | 193 |
|
|
2021
Q3 | $405K | Hold |
6,846
| – | – | ﹤0.01% | 194 |
|
|
2021
Q2 | $457K | Sell |
6,846
-864
| -11% | -$56.3K | ﹤0.01% | 198 |
|
|
2021
Q1 | $486K | Sell |
7,710
-15,300
| -66% | -$952K | ﹤0.01% | 185 |
|
|
2020
Q4 | $1.43M | Buy |
23,010
+130
| +0.6% | +$7.99K | 0.01% | 148 |
|
|
2020
Q3 | $1.38M | Sell |
22,880
-583
| -2% | -$35.1K | 0.01% | 146 |
|
|
2020
Q2 | $1.38M | Sell |
23,463
-1,178
| -5% | -$70.5K | 0.01% | 146 |
|
|
2020
Q1 | $1.37M | Sell |
24,641
-1,878
| -7% | -$115K | 0.01% | 140 |
|
|
2019
Q4 | $1.7M | Sell |
26,519
-7,361
| -22% | -$422K | 0.01% | 143 |
|
|
2019
Q3 | $1.72M | Sell |
33,880
-2,224
| -6% | -$105K | 0.01% | 140 |
|
|
2019
Q2 | $1.64M | Sell |
36,104
-6,160
| -15% | -$287K | 0.01% | 143 |
|
|
2019
Q1 | $2.02M | Sell |
42,264
-618,529
| -94% | -$30.8M | 0.01% | 136 |
|
|
2018
Q4 | $34.3M | Sell |
660,793
-29,846
| -4% | -$1.6M | 0.24% | 64 |
|
|
2018
Q3 | $34.9M | Sell |
690,639
-348,374
| -34% | -$20.7M | 0.22% | 66 |
|
|
2018
Q2 | $57.5M | Buy |
1,039,013
+241,811
| +30% | +$13.1M | 0.34% | 52 |
|
|
2018
Q1 | $50.4M | Buy |
797,202
+56,245
| +8% | +$3.62M | 0.31% | 57 |
|
|
2017
Q4 | $45.4M | Sell |
740,957
-210,247
| -22% | -$13.2M | 0.26% | 61 |
|
|
2017
Q3 | $60.6M | Sell |
951,204
-17,293
| -2% | -$1.01M | 0.36% | 54 |
|
|
2017
Q2 | $54M | Buy |
968,497
+4,278
| +0.4% | +$233K | 0.34% | 56 |
|
|
2017
Q1 | $52.4M | Buy |
964,219
+205,269
| +27% | +$11.3M | 0.33% | 58 |
|
|
2016
Q4 | $44.4M | Buy |
758,950
+222,102
| +41% | +$12.1M | 0.28% | 63 |
|
|
2016
Q3 | $28.9M | Sell |
536,848
-1,348,903
| -72% | -$86.6M | 0.2% | 72 |
|
|
2016
Q2 | $101M | Buy |
1,885,751
+1,332,163
| +241% | +$94.1M | 0.7% | 38 |
|
|
2016
Q1 | $35.4M | Sell |
553,588
-3,485
| -0.6% | -$220K | 0.25% | 66 |
|
|
2015
Q4 | $38.3M | Sell |
557,073
-22,730
| -4% | -$1.5M | 0.29% | 64 |
|
|
2015
Q3 | $34.3M | Buy |
579,803
+34,769
| +6% | +$2.21M | 0.26% | 71 |
|
|
2015
Q2 | $36.3M | Buy |
545,034
+22,328
| +4% | +$1.47M | 0.25% | 67 |
|
|
2015
Q1 | $33.7M | Buy |
522,706
+119,686
| +30% | +$7.49M | 0.23% | 67 |
|
|
2014
Q4 | $23.8M | Sell |
403,020
-8,860
| -2% | -$500K | 0.15% | 77 |
|
|
2014
Q3 | $21.1M | Buy |
411,880
+395,367
| +2,394% | +$19.7M | 0.13% | 80 |
|
|
2014
Q2 | $801K | Buy |
16,513
+300
| +2% | +$14.8K | ﹤0.01% | 127 |
|
|
2014
Q1 | $842K | Sell |
16,213
-1,200
| -7% | -$63.9K | ﹤0.01% | 126 |
|
|
2013
Q4 | $925K | Sell |
17,413
-570
| -3% | -$29K | 0.01% | 126 |
|
|
2013
Q3 | $832K | Hold |
17,983
| – | – | ﹤0.01% | 128 |
|
|
2013
Q2 | $803K | Buy |
+17,983
| New | +$781K | ﹤0.01% | 123 |
|
Other funds holding BMY
Jarislowsky, Fraser Ltd's BMY Position: Q3 2023 in Review
Jarislowsky, Fraser Ltd sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 3,470 shares — an estimated $222K sold.
Jarislowsky, Fraser Ltd first reported a position in BMY in Q2 2013 and held it in 41 quarters. The position peaked at $101M in Q2 2016. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.
- Jarislowsky, Fraser Ltd reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
- Jarislowsky, Fraser Ltd sold 3,470 Bristol-Myers Squibb shares in Q3 2023, an estimated $222K.
- Jarislowsky, Fraser Ltd first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 41 quarters.
- Jarislowsky, Fraser Ltd's Bristol-Myers Squibb position peaked at $101M in Q2 2016.
- 2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.
Based on Jarislowsky, Fraser Ltd's 13F filing for Q3 2023, filed 6 Nov 2023.